9 March 2015 Activity of glycated chitosan and other adjuvants to PDT vaccines
Author Affiliations +
Proceedings Volume 9324, Biophotonics and Immune Responses X; 932407 (2015) https://doi.org/10.1117/12.2077276
Event: SPIE BiOS, 2015, San Francisco, California, United States
Glycated chitosan (GC), a water soluble galactose-conjugated natural polysaccharide, has proven to be an effective immunoadjuvant for treatment of tumors based on laser thermal therapy. It was also shown to act as adjuvant for tumor therapy with high-intensity ultrasound and in situ photodynamic therapy (PDT). In the present study, GC was examined as potential adjuvant to PDT-generated cancer vaccine. Two other agents, pure calreticulin protein and acid ceramidase inhibitor LCL521, were also tested as prospective adjuvants for use in conjunction with PDT vaccines. Single treatment with GC, included with PDT vaccine cells suspension, improved the therapeutic efficacy when compared to vaccine alone. This attractive prospect of GC application remains to be carefully optimized and mechanistically elucidated. Both calreticulin and LCL521 proved also effective adjuvants when combined with PDT vaccine tumor treatment.
© (2015) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Mladen Korbelik, Mladen Korbelik, Judit Banáth, Judit Banáth, Evaldas Čiplys, Evaldas Čiplys, Zdzislaw Szulc, Zdzislaw Szulc, Alicja Bielawska, Alicja Bielawska, Wei R. Chen, Wei R. Chen, "Activity of glycated chitosan and other adjuvants to PDT vaccines", Proc. SPIE 9324, Biophotonics and Immune Responses X, 932407 (9 March 2015); doi: 10.1117/12.2077276; https://doi.org/10.1117/12.2077276

Back to Top